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Abstract
Background: Fabry disease is an X-chromosomally inher-
ited lysosomal storage disorder leading to accumulation of
glycosphingolipids, mainly globotriaosylceramide (cera-
mide-trihexoside, Gb3). Concentrations of Gb3 in plasma
and urine have been used to diagnose Fabry disease and to
monitor enzyme replacement therapy with recombinant a-
galactosidase.
Methods: Gb3 was purified from plasma or urine by com-
bined liquid extraction/protein precipitation and solid-phase
extraction, and was detected by flow-injection analysis elec-
trospray mass spectrometry (MS) using multi-reaction-mon-
itoring. Calibration was performed via standard addition
using C17-Gb3 as internal standard. The most abundant iso-
forms were monitored for calculation of total Gb3.
Results: A MS-based assay for quantification of Gb3 in plas-
ma and urine was established and validated. Intra- and inter-
assay coefficient of variation (CV) of the method were
F12%. However, at low concentrations the CV was 16%.
The linear range covers roughly two orders of magnitude,
down to 0.54 mg/L in plasma and 0.07 mg/L in urine. Care-
ful adjustment of tuning parameters was necessary to obtain
identical isoform intensities and quantitative results on dif-
ferent mass spectrometers. Gb3 concentrations in healthy
controls were -4 mg/L in EDTA-plasma and -10 mg/mmol
creatinine in urine. Significantly increased Gb3 concentra-
tions were found in plasma and urine from male and female
patients with Fabry disease.
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Conclusions: An improved MS protocol for Gb3 quantifi-
cation has been developed, validated, and shown to be suit-
able for diagnosis and monitoring of Fabry patients.
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Introduction
Globotriaosylceramide (Gb3), a trisaccharide linked sphin-
golipid (see Figure 1 for structure details), is the most abun-
dant and common accumulation product in patients with
Fabry disease, an X-chromosomally inherited lysosomal stor-
age disorder (1–3). The genetic defect affects the enzyme
a-galactosidase which is necessary to cleave a terminal, non-
reducing a-D-galactose from a glycan moiety (4, 5). As a
consequence, this glycan degradation pathway is blocked and
corresponding glycans, including Gb3, accumulate in tissues
primarily in the central nervous system, skin, kidney and
muscles (including heart). Typical signs are neuropathic pain,
fatigue and depression, angiokeratomas, hypohydrosis, gas-
trointestinal disorders, eye anomalies (cornea verticilata,
Fabry-cataracts), hearing impairment, chronic infection, late
puberty onset, and altered or delayed skeletal growth (6, 7).
Progression of the disease in adolescent and adult patients
may compromise brain, kidney and heart function, leading
to high morbidity and mortality due to renal failure and
ischemic events, such as stroke and myocardial infarction
(8–11).
Gb3 concentrations in plasma and urine of patients with
Fabry disease were found to be increased (12), albeit with
considerable individual variation (11). Quantification of Gb3
supports initial diagnosis and has been applied for monitor-
ing the progression of Fabry disease (13). Data suggest that
monitoring Gb3 may be of particular significance in cases
of enzyme replacement therapy (ERT) (14).
Amphiphilic glycolipids can be extracted from tissue,
blood or urine by mixtures of organic solvents, such as ace-
tone, chloroform and methanol. Early assays for glycosphin-
golipid analysis were based on thin layer chromatography
(15–18), gas chromatography (15, 17) or HPLC using
reversed phase (19) or normal phase (20–23) chromatogra-
phy. A method using sequential HPLC and high performance
thin layer chromatography was also successfully applied
(24). All these methods are usually time consuming, and
require deacylation and/or derivatization steps. An immu-
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Figure 1 Structure of the glycolipid Gb3.
Gb3 belongs to the group of neutral glycosphingoplipids and consists of a trisaccharide linked to a ceramide moiety (N-acylsphingosine).
The trisaccharide is composed of 1–4 linked b-D-glucose, b-D-galactose and a-D-galactose (Gal(a1™4)Gal(b1™4)Glc(b1™1)ceramide).
The fatty acid component linked via the amide bond exhibits a high degree of heterogeneity, whereas the sphingosine alkyl chain is almost
homogenous (mainly C18:1). The arrow marks the bond which is cleaved by the enzyme a-galactosidase, lacking in Fabry patients, where
also the specific fragmentation for mass spectrometric detection occurs (loss of one galactose moiety, –162 m/z).
noassay (ELISA) was developed in 1999 (25). However,
with the advent of mass spectrometry (MS), faster and more
specific methods have been developed. Detection of Gb3 by
MS has been achieved by fast-atom-bombardement (FAB)
(26), and matrix-assisted laser desorption-ionization (MAL-
DI) has been used for detection and relative quantification
of Gb3 and other sphingolipids for disease classification
(27). Tandem MS methods for absolute quantification usually
rely on specific fragmentation using electrospray ionization
combined with multi-reaction-monitoring (MRM). Gb3 can
be monitored by a specific loss of one galactose residue
(–162 m/z) from the sodiated precursor ion. Suitable meth-
ods which use protein precipitation and liquid or solid phase
extraction (SPE) in combination with flow-injection analy-
sis-MS (FIA-MS) have been described (28–31). Due to the
hydrophobic nature of Gb3, reversed phase chromatography
in combination with MS is challenging with respect to mem-
ory effects and tailing. One solution is to use very short
columns with low hydrophobicity. Nelson et al. and Mills et
al. described a liquid chromatography-tandem mass spec-
trometry (LC-MS) method that used two short C8 guard col-
umns and a tertiary gradient to ensure complete lipid
washout (32–35). Delobel et al. performed structural analysis
of Gb3 species using a porous graphitic column and atmo-
spheric pressure photoionization (APPI) (36).
However, for robust quantitative routine assays, it can be
advantageous to omit the chromatographic step and to rely
instead on extraction and purification steps during sample
preparation. Based on earlier approaches, we describe an
improved methodology using combined liquid extraction/
protein precipitation, normal phase SPE and FIA-MS-MRM,
and its application to clinical monitoring of Gb3 concentra-
tions in plasma and urine of patients with Fabry disease.
Materials and methods
Patients
Blood and urine samples from healthy volunteers and Fabry patients
were collected after obtaining informed consent. Patients were
included in Fabry Outcome Survey (FOS), which was approved by
the Ethics Committee/Institution Review Board of all participating
centers. The age (years) distribution was as follows wshown as medi-
an (mean) and rangex controls plasma (ns50), 27.5 (30.4), 19–54;
male Fabry plasma (ns87), 29 (32.0), 8–68; female Fabry plasma
(ns122), 36 (36.1), 6–69; controls urine (ns89), 38 (40.1), 19–68;
male Fabry urine (ns71), 29 (31.0), 8–56; female Fabry urine
(ns117), 36 (36.1), 8–70.
Chemicals and standards
Chloroform p.a. (Roth, Karlsruhe, Germany), spectroscopy grade
acetone, ethyl acetate p.a., HPLC-grade methanol (Merck, Darm-
stadt, Germany) and HPLC-grade water (Mallinckrodt-Baker,
Deventer, Netherlands) were used as solvents. The porcine Gb3 cal-
ibrator and the internal standard (ISTD) heptadecanoyl-Gb3 (C17-
CTH) were obtained from Matreya LLC (Pleasant Gap, PA, USA)
and dissolved in chloroform:methanol (2:1/v:v). The final concen-
tration of the calibrator stock solution was 40 mg/L, and the ISTD
was dissolved and diluted to a final working concentration of
0.5 mg/L. Standard addition was used for both plasma and urine
samples.
Sample preparation EDTA-plasma
For each sample, standard and control, one vial containing 1200 mL
acetone:methanol (1:1/v:v) spiked with 20 mL ISTD solution was
prepared. Seven standard concentrations were prepared in duplicate
by spiking with different volumes of Gb3 standard stock solution
(0–48 mL) to produce plasma concentrations of 0.0, 1.2, 2.4, 4.8,
9.6, 14.4 and 19.2 mg/L. 100 mL of EDTA plasma was added to
each vial. Pooled EDTA plasma was used in case of standards and
controls. Controls were prepared at two concentrations in duplicate.
Samples, standards and controls were processed identically as
described below. The vials were sonicated for 5 min, vortexed and
centrifuged for 10 min at 2800 g per min. The supernatant was
transferred into a new vial and dried in a vacuum centrifuge. Dry
samples may be stored at –208C for later processing.
Sample preparation urine
For each sample, standard and control, one vial containing 1200 mL
chloroform:methanol (2:1/v:v) spiked with 20 mL ISTD solution
was prepared. Seven standard concentrations were prepared in dupli-
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Figure 2 Mass spectrum of porcine Gb3 standard obtained using
two different triple quadrupole mass spectrometers.
(A) TSQ Quantum Discovery Max (Thermo Electron); (B) Quattro
Premier XE (Waters).
cate by spiking with different volumes of Gb3 standard stock solu-
tion (0–36 mL) to produce urine concentrations of 0.0, 0.3, 0.6, 1.2,
2.4, 4.8 and 7.2 mg/L. 200 mL urine from a 24-h collection was
added to each vial. Pooled urine samples were used for standards
and controls. Controls were prepared in duplicate at two concentra-
tions. All other steps were identical to those described for plasma.
Solid-phase-extraction
Normal phase SPE was identical for plasma and urine samples.
Silica SPE columns (Bond Elut Straight Barrel Cartridges, 100
mg/1 mL, Varian, Palo Alto, CA, USA), were washed and equili-
brated 3 times with 1 mL of methanol and 3 times with 1 mL of
chloroform. Gb3 pellets were redissolved in 1 mL of chloroform
with subsequent sonication for 5 min, thorough vortexing and
centrifugation at 13,000 g for 10 min. The redissolved samples were
applied onto the SPE-columns. The columns were washed 3 times
with 1 mL of chloroform and 3 times with 1 mL of ethyl acetate.
Gb3 was eluted with 3 mL of acetone:methanol (8:2/v:v) and dried
in a vacuum centrifuge.
Mass spectrometry
Quantification of Gb3 was performed using electrospray MS with
a triple-quadrupole instrument (TSQ Quantum Discovery Max,
Thermo Scientific, Waltham, MA, USA). Sample introduction was
performed with a standard HPLC pump and autosampler (Surveyor,
Thermo Scientific). For comparison of potential instrument effects,
an ion-trap mass spectrometer (LCQ Deca with Surveyor HPLC,
Thermo Scientific, Waltham, MA, USA) and another triple quadru-
pole mass spectrometer (Quattro Premier XE with Acquity UPLC,
Waters, Milford, MA, USA) were also used.
Samples were redissolved in 100 mL of methanol with subse-
quent sonication for 5 min, thorough vortexing and centrifugation
at 13,000 g for 10 min. The supernatant was transferred into glass
microvials. Samples were introduced into the mass spectro-
meter by FIA (15 mL) using pure methanol at a flow rate of
150 mL/min. Two short blank runs (25 mL methanol, 1.5 min run
time, 200 mL/min) were injected between samples for washout. Gb3
was monitored by MRM using the specific loss of one galactose
unit (–162 m/z) from the sodium adducts as a marker of fragmen-
tation. Since Gb3 is not homogeneous with respect to the fatty acid
composition, transitions for the most abundant isoforms were select-
ed (length, saturation degree and oxidation status of the fatty acid
moiety are given in parentheses): m/z 1046.7 (C16:0), m/z 1060.7
(C17:0, ISTD), m/z 1130.8 (C22:0), m/z 1146.9 (C22:0-OH), m/z
1156.9 (C24:0), m/z 1158.9 (C24:1), m/z 1174.9 (C24:0-OH).
The optimized instrument conditions were as follows:
TSQ Quantum: spray voltage 3.0 kV, sheath gas 20 AU, auxiliary
gas 4 AU, capillary temperature 3808C, source CID 7 V, tube lens
offset 230 V, collision energy 62 eV.
Quattro Premier: spray voltage 3.7 kV, desolvation gas 500 L/h,
cone gas 25 L/h, desolvation temperature 2008C, source temperature
608C, cone voltage 110 V, collision energy 68 eV.
LCQ Deca: spray voltage 3.0 kV, sheath gas 9 AU, auxiliary gas 0
AU, capillary temperature 2408C, source CID 100 V, capillary volt-
age 45 V, tube lens offset 35 V, collision energy 46%.
Data processing
Peak integration was checked and corrected where necessary using
either Xcalibur (Thermo Scientific) or MassLynx software (Waters).
Data were exported to Excel. Quantification of total Gb3 was
achieved by summing up the intensities of the Gb3 isoforms and
dividing by the intensity of the ISTD. Since no Gb3-free plasma is
available, standard addition was applied for calibration. Gb3 con-




The method was evaluated according to quality system pro-
cedures prior to approval for routine analysis. Calibration
was performed via standard addition of porcine Gb3 (see
Figure 2). Calibration curves (7 concentrations) were linear,
with regression coefficients (r2) )0.99 for urine, and 0.98
for plasma. The lower value for plasma was due to the higher
background of plasma pools used for spiking. The average
of the correlation coefficients obtained between October 17,
2005 and December 31, 2007 was r2s(0.9929"0.0099) for
urine and r2s(0.9871"0.0252) for plasma.
Intra- and inter-assay imprecision were measured at two
concentrations, representative of Fabry patients and healthy
controls (see Table 1). Pooled samples were used for this
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Table 3 Stability data following storage at –208C (each value is the mean of six analyses).
Pool Storage time, year Plasma Urine
Mean, mg/L Deviation, % Mean, mg/L Deviation, %
Low 1/2 4.82 –2.2 0.57 –10.5
High 1/2 9.92 q2.1 5.91 q2.7
Low 1 4.96 q3.2 0.47 –21.1
High 1 10.97 –1.35 5.49 q5.7
Table 2 Linearity results for Gb3 quantification (dilution series).
Dilution series Plasma Urine low Urine high
Mean value"SD, mg/L 10.98"0.38 3.14"0.18 6.81"0.10
CV% 3.50 5.61 1.48
Recovery"SD, % 100.55"3.69 100.14"3.77 100.04"1.78
Recovery max, % 104.8 107.8 102.7
Recovery min, % 92.3 94.8 96.2
Linear range, mg/L 0.54–10.86 0.07–3.28 0.17–6.72
Linear regression ys1.0362x–0.1598 ys1.0030x–0.0122 ys1.0028xq0.0046
Regression coefficient, r2 0.9957 0.9993 0.9997
Table 1 Imprecision results for Gb3 quantification.
Plasma Urine
Mean, mg/L CV% n Mean, mg/L CV% n
Intra-assay
Low 3.06 6.75 10 0.56 15.59 11
High 10.11 3.86 10 4.84 12.15 11
Inter-assay
Low 5.02 10.22 29 0.44 16.15 23
High 11.03 11.13 29 5.63 10.53 26
purpose. Intra-assay imprecision was determined by analyz-
ing individually prepared sample aliquots (ns10–11) in one
batch. Inter-assay imprecision was obtained by analyzing
aliquots (ns23–29) in different runs on different days.
Coefficient of variation (CV) ranged from 4% to 12%, with
the exception of 16% for urine with low concentrations.
However, inter-assay imprecision in plasma and urine was
comparable at higher Gb3 concentrations.
Linearity was assessed by serial dilution of Gb3 samples.
The results are expressed as recovery (deviation from the
mean), together with the correlation coefficient and the
assessed linear range (see Table 2). In the concentration
range tested, recoveries"standard deviation (SD) were
100%"4% for plasma and 100%"2% for urine, with a min-
imum and maximum recovery of 92% and 108%, respec-
tively. Regression coefficients were )0.995 for plasma and
)0.999 for urine. The method proved to be linear down to
0.54 mg/L for EDTA plasma and down to 0.07 mg/L for
urine (two dilution series). The signal-to-noise ratio (S/N)
upon repeated analysis of patient pools was used to calculate
analytical sensitivity. The limit of detection (S/N 3:1) was
0.02 mg/L for plasma and 0.01 mg/L for urine.
Aliquots from Fabry patient pools (two concentrations)
were frozen at –208C and used as quality control samples.
Frozen plasma samples were stable for at least 1 year, where-
as Gb3 in urine samples showed a decrease in the low con-
centration range of up to 20% after 1 year (compare stability
values in Table 3).
Instrument comparison
Initial experiments for method development have been per-
formed with a quadrupole ion trap (LCQ Deca, Thermo Elec-
tron) using selective reaction monitoring. After subsequent
evaluation and method approval of a MRM method with a
triple quadrupole (TSQ Quantum, Thermo Electron), a set of
89 patient samples was used to perform an instrument com-
parison (Figure 3A). Correlation between the results was
high (r2)0.96), but the ion trap results were systematically
lower. Consequently, the routine assay was performed exclu-
sively with the triple quadrupole, an instrument type which
is known for its excellent quantification performance.
With the growing number of samples from two multicenter
studies wFOS (37–39), and Stroke in Young Fabry Patients
(SIFAP) (10)x, the question of a method transfer to another
instrument became apparent. Thus, we started to evaluate the
method using another triple quadrupole MS (Quattro Premier
XE, Waters). To our surprise, distinct deviations were
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Figure 3 Instrument comparison.
Gb3 was extracted from EDTA plasma or urine of patients with confirmed and suspected Fabry disease, and the purified samples were
analyzed with different mass spectrometers. (A) Comparison of two mass spectrometer types (ns89): a triple-quadrupole mass spectrometer
(TSQ Quantum Discovery Max, Thermo Scientific) and a quadrupole ion trap (LCQ Deca XP, Thermo Scientific). Both instruments were
equipped with Surveyor autosampler and HPLC pump. (B–D) Comparison of two different triple quadrupole mass spectrometers: TSQ
Quantum Discovery Max (Thermo Scientific) equipped with a Surveyor autosampler and HPLC pump, and Quattro Premier XE (Waters)
equipped with Acquity autosampler and UPLC pump. (B) shows the obtained correlation using identical collision voltage (62 V) and similar
quadrupole resolution (ns33). (C) (EDTA-plasma, ns93) and (D) (urine, ns35) show the obtained correlations after careful adjustment
of instrument parameters.
observed even between the two triple quadrupoles (see Fig-
ure 3B). The values obtained on the Quattro Premier were
significantly higher, although the correlation was excellent
with an r2)0.99.
At first glance, no difference would be expected using the
same type of instrument. However, heterogeneity of Gb3
may influence quantification results. Since no obvious dif-
ference was observed in the full scan survey spectra (see
Figure 2), we examined whether different isoform profiles
appear in the MRM modus. The relative MRM abundancies
of human Gb3 isoforms in plasma and urine from patients
with Fabry disease, before and after spiking with porcine
Gb3 standard, are shown in Figure 4.
In addition to the obvious differences between plasma and
urine, and also upon spiking, small but discernable devia-
tions in the isoform profiles were observed with the two
triple quadrupoles. We suspected that this effect might be
related to different fragmentation efficiencies and/or resolu-
tion settings. This assumption and the influence of these
parameters on the isoform profile were verified by recording
Gb3 MRM spectra at different collision offsets and quadru-
pole resolution settings (see Figure 5).
After this finding, tuning conditions were adapted such
that almost identical isoform abundancies were obtained on
either instrument. It turned out that the appropriate collision
energy was 68 eV using the Quattro Premier, in contrast to
62 eV with the TSQ Quantum. With these new settings, cor-
relation was now appropriate with negligible quantitative
deviations (see Figure 3C and D).
Gb3 levels in Fabry patients and healthy controls
The successful evaluation of the method qualifies its routine
application in a clinical setting. However, the differences
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Figure 4 Relative MRM abundancies of Gb3 isoforms in plasma and urine of Fabry patients before and after spiking with porcine Gb3
standard.
The obtained average isoform abundancies (m/z values) were normalized by setting the highest isoform to 100%. The bar graphs on the
left show the intensity distribution in plasma (A) and urine (C) of Fabry patients. The bar graphs on the right depict the situation after
adding the porcine Gb3 spike (B: plasma, spike 19.2 mg/L; D: urine, spike 7.2 mg/L). For comparison, the results obtained with two
different mass spectrometers are shown. It is readily apparent that the lower isoforms (m/z 1046) are underrepresented in the TSQ Quantum
(Thermo Scientific) compared to the Quattro Premier XE (Waters). Moreover, plasma and urine show considerably different isoform profiles.
observed on various MS platforms support the necessity for
determining method-specific reference ranges. Gb3 concen-
trations in the patients with Fabry disease and controls are
summarized in Table 4. All ranges are shown as the 5th–95th
percentile.
Gb3 concentrations in 50 EDTA plasma samples from
healthy controls were determined with the new method using
the triple quadrupole (TSQ Quantum). The median was
2.8 mg/L, with a range of 1.7–3.6 mg/L (see Figure 6A).
Slightly lower results (15%) were obtained with the quadru-
pole ion trap (LCQ Deca), reflecting exactly the different
responses of the two instruments. However, the upper limit
of the 95th percentile was almost identical.
As expected, patients with Fabry disease show signifi-
cantly higher Gb3 plasma concentrations (p-0.0001). The
median for samples from male Fabry patients (ns34) was
6.6 mg/L with a range of 2.9–13.3 mg/L. The median for
samples from female heterozygotes (ns58) was lower at
4.1 mg/L, with a range of 2.4–5.7 mg/L.
Gb3 concentrations in urine are considerably lower, and
values near the limit of quantification are often observed,
even in Fabry patients (see Figure 6B). Gb3 values were
normalized to creatinine to correct for differences in urinary
concentrations. Values were determined with the TSQ Quan-
tum. The median in healthy controls (ns89) was 0.8
mg/mmol creatinine, with a range of 0.4–3.0 mg/mmol
creatinine. Gb3 concentrations were also significantly in-
creased (p-0.0001) in the urine of female (ns57) and male
(ns22) Fabry patients. The median Gb3 concentrations was
28 mg/mmol creatinine in women (range 1–96), and 218
mg/mmol creatinine in men (range 3–584).
Since ERT is expected to lower Gb3 concentrations in
plasma and urine, we also analyzed an independent group of
patients who were undergoing ERT for at least 6 months at
the time of blood or urine collection. There was a trend for
lower plasma and urine concentrations of Gb3 (see Table 4).
However, this difference did not reach statistical signifi-
cance. If Gb3 concentrations were analyzed in individual
patients before and after ERT, median plasma Gb3 decreased
from 9.4 to 5.3 mg/L in men (ps0.005), but was little
changed in women (3.9 and 3.8 mg/L, ps0.557). Median
urinary Gb3 decreased from 285 to 165 mg/mmol creatinine
in men, albeit with little significance (ps0.524), and from
30 to 9 mg/mmol creatinine in women (ps0.056).
Several reports suggest a correlation between genotype
and Gb3 concentrations (12, 13, 34). Therefore, we sorted
the patients into three groups: non-sense mutations, missense
mutations, and deletions/insertions and splice site defects.
Due to the small number of patients, there were no signifi-
cant differences, even though patients with missense muta-
tions tended to have lower plasma and urinary Gb3
concentrations. All men with Gb3 plasma concentrations
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Figure 5 Gb3 isoform profiles.
Gb3 isoform profiles obtained with different collision energies (A)
and quadrupole resolution settings (B) using a triple quadrupole
(Quattro Premier XE, Waters). The obtained average isoform abun-
dancies (m/z values) were normalized by setting the highest isoform
to 100%.
Table 4 Gb3 concentrations of the patient groups with and without enzyme replacement therapy (ERT); ranges5th–95th percentile.
Plasma Gb3, mg/L Urine Gb3, mg/mmol creatinine
n Mean Median Range n Mean Median Range
Controls 50 2.8 2.8 1.7–3.6 89 1 0.8 0.4–3
Fabry male
Without ERT 34 7.3 6.6 2.9–13.3 22 221 218 3–584
ERT 53 6.2 5.9 2.8–11.2 49 261 52 2–907
Fabry female
Without ERT 58 4.1 4.1 2.4–5.7 57 33 28 1–96
ERT 64 4.2 4.1 2.7–5.9 60 22 12 3–50
within the reference range had missense mutations, which is
consistent with previous reports (34). However, from eight
patients (four male, four female) with the cardiac variants
R112H or N215S, two women and one male presented with
moderately, but clearly increased plasma concentrations up
to 5 mg/L, albeit normal urine Gb3.
Discussion
Methodic considerations and method performance
Heterogeneity and the amphiphilic nature of Gb3 dominates
considerations for establishment of a routine test. In order to
avoid surface adsorption, tailing and memory effects on the
column, we chose offline sample preparation using sequen-
tial liquid extraction and SPE instead of online LC-MS.
Protein precipitation and Gb3 extraction with acetone:
methanol (1:1/v:v) gave good results with EDTA plasma.
Lipid extraction with chloroform:methanol (2:1/v:v) was
used for urine. In contrast to other protocols (30, 32), ana-
lytes were enriched using a silica stationary phase as a sec-
ond purification step. Due to an initial liquid extraction and
subsequent redissolution in pure chloroform, proteins and the
majority of polar contaminants and salts are eliminated
before samples are applied to the normal phase column. Sub-
sequently, lipids, such as triglycerides and cholesterol esters
are washed off the column with chloroform, whereas amphi-
philic analytes with polar moieties are trapped on the silica
and can be eluted with solvents of higher polarity. Ace-
tone:methanol 4:1 (v:v) was found to be suitable for elution
of Gb3.
Since calibration with pure standards is not possible due
to strong matrix suppression effects, and matrix-matched
human Gb3 standards are not available, we decided in favor
of standard addition instead. In addition, differences during
sample preparation and fluctuations during ESI detection are
compensated by addition of a suited ISTD with a non-natural
fatty acid (C17), synthesized from natural Gb3 by reacylation
of deacylated Gb3 with heptadecanoic acid (28). With
respect to the ISTD, it is important to mention that FIA has
another advantage compared to online LC-MS: compensa-
tion for ionization fluctuations and matrix suppression effects
requires simultaneous elution of analyte and ISTD into the
MS. This is easily achieved by FIA, whereas chromatograph-
ic separation of different Gb3 isoforms, including the ISTD,
is difficult to avoid during LC-MS.
The variability of isoform abundancies is another issue to
be addressed. The only available source for calibration stan-
dards, Gb3 from porcine erythrocytes, contains primarily iso-
forms with comparably long fatty acid chains (mainly C22,
C24, see Figure 2). In contrast, isoforms with short fatty
acids are most abundant in blood plasma, especially C16:0
(m/z 1046, sodiated precursor). Longer fatty acids are usually
found in urine (30). It should be noted that Nelson et al.
observed strong variations of isoform profiles with LC-MS,
requiring thorough rinsing (32). Since absorption by capil-
lary walls and in the injector is critical, even during FIA, the
inlet was washed after each sample by injection of methanol
blanks using short 1.5 min runs.
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Figure 6 Comparison of plasma and urine Gb3 concentrations in Fabry patients without ERT and healthy controls.
(A) Gb3 concentrations in EDTA plasma samples from 34 male Fabry patients, 58 female Fabry patients and 50 healthy controls were
determined with the described method using the TSQ Quantum triple quadrupole. Both groups were found to be significantly different from
the control group with p-0.0001. Median Gb3 concentrations in mg/L were: male Fabry patients 6.6 (mean 7.3), female Fabry patients
4.1 (mean 4.1), and controls 2.8 (mean 2.8). (B) Gb3 concentrations in urine samples from 22 male Fabry patients, 57 female Fabry patients
and 89 healthy controls were determined with the described method using the TSQ Quantum triple quadrupole. Both groups were found to
be significantly different from the control group with p-0.0001. Median Gb3 levels in mg/mmol creatinine were: male Fabry patients 218
(mean 221), female Fabry patients 28 (mean 33), and controls 0.8 (mean 1). The square represents the mean average and the line within
the box represents the median. The box represents the 25th–75th percentile, and the whiskers represent the 5th–95th percentile (see text
for range numbers). The crosses represent the 1st–99th percentile, and the dash gives the maximum and minimum values, respectively.
In order to cover the heterogeneous isoform profiles of all
materials, total Gb3 was calculated by summing the most
abundant isoforms present in plasma, urine and porcine Gb3.
However, a certain intrinsic bias cannot be completely avoid-
ed since the number of parallel MRM transitions is limited,
and monitoring a high number of isoforms leads to poor duty
cycles and low intensities. Monitoring of six isoforms plus
ISTD was a good compromise between accuracy and signal
intensity, and produced reproducible results. The method
covers the concentration range for monitoring Gb3 in plasma
and urine, and allows for accurate and robust long-term mon-
itoring of Fabry patients.
Influence of isoform profiles and instrument
comparison
The observed deviations between different mass spectrome-
ters are related to the fact that mass-dependent sensitivity is
instrument-dependent and can influence the relative signal
height of Gb3 isoforms. Due to different abundancies of iso-
forms in standards and samples, any mass-dependent sensi-
tivity difference would necessarily result in systematic
deviations upon calibration. For instance, CID fragmentation
in ion traps occurs via multiple low-energy collisions, where-
as single high-energy collisions are the dominant fragmen-
tation pathway in collision-cells of triple quadrupoles.
Moreover, the limited linear range and ion capacity of ion
traps is known to affect quantitation performance. Hence, the
observed instrumental deviation between ion trap and triple
quadrupole may be expected. However, the good correlation
indicates that reliable and reproducible results are obtained
on either instrument.
At first glance, no deviation would be expected between
two triple quadrupoles. However, there are several instru-
ment differences and parameter settings that might lead to
changes in the isoform profiles obtained. For example, ion
desolvation in the TSQ Quantum is achieved with use of a
heated capillary, whereas the Quattro Premier utilizes a heat-
ed nitrogen counter flow. Differences in collision efficiency
may also lead to varying detection efficiencies upon MRM
of Gb3 isoforms, even at identical collision energies. Indeed,
experiments showed that collision energy and quadrupole
resolution had the greatest influence on isoform distribution,
and remarkably different collision energies were necessary
in order to obtain comparable isoform profiles and consistent
quantitative results with the two instruments. The influence
of the quadrupole resolution can be explained by crosstalk
from neighbored isoform isotopes, especially if low resolu-
tion settings are used. Most likely, the effect of collision
energy reflects the influence of the fatty acid chain length
on activation energy, and therefore fragmentation efficiency.
It has to be noted that due to the lack of certified reference
standards and methods, there is currently no statement pos-
sible about the accuracy of either method. In principal, dif-
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ferent methods can be used successfully even without exact
matching of the results, provided appropriate reference rang-
es are taken into account. However, universal reference
ranges are highly preferable, requiring careful adjustment of
instrumental conditions to ensure equal results.
Reference ranges
Male and female Fabry patients have significantly higher
Gb3 plasma concentrations compared to controls. Although
low Gb3 concentrations do not necessarily exclude the exis-
tence of Fabry disease, especially in women who generally
show lower Gb3 concentrations, high Gb3 values above
4.0 mg/L strongly support the diagnosis of Fabry (3rd–97th
percentile TSQ, 5th–95th percentile LCQ). Consequently, the
cut-off for the routine assay was set to 4.0 mg/L. At this cut-
off threshold, specificity was 98%, with a sensitivity of 79%
for male Fabry patients and a sensitivity of 54% for female
Fabry patients.
In urine from healthy controls, very low Gb3 concentra-
tions were measured that were essentially equivalent to the
background of the assay. Consequently, urinary Gb3
)10 mg/mmol creatinine gives strong evidence for Fabry
disease. At this cut-off, specificity was 100%, with a sensi-
tivity of 77% for male Fabry patients and a sensitivity of
65% for female Fabry patients.
Significantly increased urine Gb3 concentrations in Fabry
patients were frequently observed, occasionally above
1000 mg/mmol creatinine. However, many Fabry patients
have very low urinary Gb3 concentrations, and normal urine
Gb3 does not exclude the possibility of Fabry, similar to the
situation in plasma. In addition, increased urine concentra-
tions do not necessarily coincide with increased plasma val-
ues. A correlation with the type of mutation was suggested
to explain this observation (12).
However, it remains still unclear as to what extent genetic
variations are important for the abundance of Gb3 in plasma
or urine of Fabry patients. We found only weak correlation
with the type of mutation, except that patients with low Gb3
usually have missense mutations. In contrast, we also
observed patients with cardiac variants and increased Gb3
plasma concentrations. These observations indicate that a
simple classification is probably not appropriate, and indi-
vidual mutations need to be treated separately with respect
to the effect on enzyme structure and Fabry outcome. Further
investigations on this topic will be performed.
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